KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash & Equivalents (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Cash & Equivalents for 18 consecutive years, with $173.4 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 34.37% year-over-year to $173.4 million; the TTM value through Mar 2026 reached $173.4 million, down 34.37%, while the annual FY2025 figure was $372.3 million, 53.78% up from the prior year.
  • Cash & Equivalents hit $173.4 million in Q1 2026 for Ionis Pharmaceuticals, down from $372.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $542.5 million in Q1 2022 and bottomed at $173.4 million in Q1 2026.
  • Average Cash & Equivalents over 5 years is $341.5 million, with a median of $334.6 million recorded in 2024.
  • Year-over-year, Cash & Equivalents tumbled 68.19% in 2022 and then soared 53.78% in 2025.
  • Ionis Pharmaceuticals' Cash & Equivalents stood at $276.5 million in 2022, then skyrocketed by 44.41% to $399.3 million in 2023, then tumbled by 39.37% to $242.1 million in 2024, then skyrocketed by 53.78% to $372.3 million in 2025, then crashed by 53.42% to $173.4 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $173.4 million, $372.3 million, and $338.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.